Comparison of Effect-site Concentration of Remifentanil for Preventing Cough Against Endotracheal Tube During Anesthetic Emergence According to Anesthetics (Sevoflurane, Desflurane, and Propofol)

The recruitment status of this study is unknown because the information has not been verified recently.

Verified May 2011 by Yonsei University.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Yonsei University

ClinicalTrials.gov Identifier:

NCT01351285

First received: May 4, 2011

Last updated: May 9, 2011

Last verified: May 2011

History of Changes

Tracking Information

First Received Date ^ICMJE

May 4, 2011

Last Updated Date

May 9, 2011

Start Date ^ICMJE

April 2011

Estimated Primary Completion Date

April 2012 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

occurrence of cough [ Time Frame: From the completion of surgery to 5minute after extubation ] [ Designated as safety issue: No ]

We will assess the occurrence of cough during emergence from general anesthesia in female patients undergoing target controlled infusion of remifentanil at predetemined concentration.

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT01351285 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Comparison of Effect-site Concentration of Remifentanil for Preventing Cough Against Endotracheal Tube During Anesthetic Emergence According to Anesthetics (Sevoflurane, Desflurane, and Propofol)

Official Title ^ICMJE

Not Provided

Brief Summary

It has been reported that target-controlled infusion of remifentanil can reduce cough against endotracheal tube during emergence from general anesthesia. We hypothesized that effective concentration of remifentanil for preventing cough during anesthetic emergence varies depending on the type of main anesthetic agents which is administered with remifentanil during general anesthesia. The purpose of this study is to evaluate the effective concentrations of remifentanil to prevent coughing during emergence from general anesthesia according to main anesthetic agent (sevoflurane, desflurane, and propofol).

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Not Provided

Study Design ^ICMJE

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)

Condition ^ICMJE

Female Patients Undergoing Thyroidectomy

Intervention ^ICMJE

Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough

During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.

Study Arm (s)

Experimental: Sevo group
undergoing sevoflurane-remifentanil anesthesia

Intervention: Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough
Active Comparator: Des group
undergoing desflurane-remifentanil anesthesia

Intervention: Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough
Active Comparator: Pro group
undergoing propofol-remifentanil anesthesia

Intervention: Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Estimated Enrollment ^ICMJE

Estimated Completion Date

April 2012

Estimated Primary Completion Date

April 2012 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

aged 20-60
ASA classification I~II
female patients
patients who undergoing thyroidectomy

Exclusion Criteria:

Patients with acute or chronic respiratory disease
patient who has smoking history
patient who has hypertension
patient who has esophageal reflux
patient who having an expectorant or cough remedy

Gender

Female

Ages

20 Years to 60 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Jeong Rim Lee

82-2228-2420

MANYA@yuhs.ac

Location Countries ^ICMJE

Korea, Republic of

Administrative Information

NCT Number ^ICMJE

NCT01351285

Other Study ID Numbers ^ICMJE

4-2011-0019

Has Data Monitoring Committee

Responsible Party

Jeong Rim Lee/Assistant professor, Severance Hospital

Study Sponsor ^ICMJE

Yonsei University

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Not Provided

Information Provided By

Yonsei University

Verification Date

May 2011

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top